Jefferies downgrades Genmab recommendation due to lack of short-term catalysts

A lack of short-term catalysts is one of the reasons that investment bank Jefferies has changed its recommendation for Genmab stock. The biotech company's share price increase since the start of the year is another reason, as S&P's biotech index has fallen during the same period.
Photo: Tuala Hjarnø / Genmab / PR
Photo: Tuala Hjarnø / Genmab / PR

US-based investment bank Jefferies has downgraded its recommendation for Genmab from "buy" to "hold," as the share price has risen by around 10 percent since the start of the year and 40 percent since March, while S&P's index has fallen 9 percent since the New Year.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading